Alzheimer’s medicine created by Eli Lilly and Co. reduced cognitive decline by 35%
The medicine, donanemab, achieved every trial target. According to Lilly, in 1,182 patients with early-stage Alzheimer's who had scans showing amyloid protein deposits in the brain and intermediate levels of…